FDA warns Novo Nordisk of potential unreported GLP-1 side effects
The FDA issued a warning letter to Novo Nordisk — the maker of Ozempic and Wegovy — for failing to report potential side effects in patients who took its blockbuster medications.
The Ultimate Grocery List for GLP-1 Users, According to a Dietitian
These kitchen staples are nutrient-dense and easy to tolerate.
FDA warns Novo Nordisk over unreported potential Ozempic side effects
The FDA issued a warning letter to Novo Nordisk, the Danish drugmaker behind the diabetes and weight-loss medications Ozempic and Wegovy, over unreported potential side effects.
GLP-1 Drugs and Osteoporosis; HbA1c at the Dentist? New Obesity Med Guide
(MedPage Today) — GLP-1 receptor agonists may increase the risk of bone and tendon injuries, as well as conditions like osteoporosis and gout, a retrospective study suggested. (Washington Post)
Chairside HbA1c testing during routine dental visits…
2018 to 2025 Saw Rise in GLP-1 Receptor Agonist Rx for Bariatric Surgery-Eligible Patients
TUESDAY, March 10, 2026 — Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescriptions increased from 2018 to 2025, while MBS use decreased beginning in 2023, according to a…
Ascletis touts GLP-1 quarterly dosing data; Mineralys apnea Phase 2 misses
Plus, news about Telix Pharmaceuticals, Laekna, Prothena, Novo Nordisk, Keymed Biosciences, AstraZeneca and f5 Therapeutics:
📊 Ascletis trumpets potential quarterly dosing of GLP-1: An investigational subcutaneous depot formulation of Ascletis’s GLP-1 drug ASC30 …
STAT+: Novo Nordisk is warned by the FDA for failing to report side effects tied to GLP-1 drugs
It’s the third time in recent weeks that the FDA has admonished Novo Nordisk for different practices.
GLP-1s have transformed weight loss and diabetes. Is addiction next?
A large study found that people taking GLP-1 drugs like Ozempic for diabetes were less likely to be diagnosed with substance use disorder.
Can You Maintain Weight Loss With Fewer Injections of Ozempic, Wegovy?
A small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections. Image Credit: Siluk/UCG/Universal Images Group via Getty Images
A recent small study found that reduced GLP-1 frequency may help people maintain their weight loss.
The study shows that people who dosed as little as once every two months maintained weight loss and other improved health markers.
AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
NORTH CHICAGO, Ill., March 9, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and…